CompletedPhase 2NCT01401257
Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A
Studying Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pharnext S.C.A.
- Principal Investigator
- Shahram ATTARIAN, MDHôpital La Timone
- Intervention
- PXT3003 Low dose(drug)
- Enrollment
- 80 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2010 – 2012
Study locations (6)
- Hôpital Roger Salengro, Lille, France
- CHU Dupuytren, Limoges, France
- CHU Lyon Sud, Lyon, France
- Hôpital La Timone, Marseille, France
- Hôtel Dieu, Nantes, France
- Groupe Hospitalier Pitié-Salpétrière, Paris, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01401257 on ClinicalTrials.govOther trials for Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07038239Genotype/Phenotype Correlation of MORC2 MutationsHospices Civils de Lyon
- RECRUITINGNCT06203093Charcot-Marie-Tooth Disease (CMT) Biological Sample Collection for IPSC Generation and BiobankingNew York Stem Cell Foundation Research Institute
- RECRUITINGNCT05902351Natural History Study for Charcot Marie Tooth DiseaseHereditary Neuropathy Foundation
See all trials for Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons →